Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Number of infusion reactions classified according to grade of seriousness

From: Predictors of infusion reactions during infliximab treatment in patients with arthritis

Group Grade of seriousness Infusion reactions
   All Infliximab dosage unchanged Infliximab dosage increased at 3–6 months Infliximab dosage increased at 6–12 months Infliximab dosage increased at 12 months
RA patients (n = 45) Life threatening 2 1 1 0 0
  Serious 16 11 2 1 2
  Moderate 24 15 8 5 6
  Mild 3 1 0 1 1
SpA patients (n = 10) Life threatening 0 0 0 0 0
  Serious 6 4 1 1 0
  Moderate 2 1 1 0 0
  Mild 2 1 1 1 0
  1. RA, rheumatoid arthritis; SpA, spondylarthropathy.